Office of Research
Innovations in Clinical Research Award
Note: This is not a limited submission opportunity and is posted for informational purposes only.
The Doris Duke Innovations in Clinical Research Award (ICRA) provides funding for early-stage research projects in clinical investigation to foster innovations in clinical research that advance the prevention, diagnosis and treatment of human disease. DDCF seeks proposals for cutting-edge clinical research that has the potential to catalyze innovative breakthroughs in sickle cell disease. Research areas of interest to the foundation are listed in our Request for Letters of Intent.
In keeping with the wishes expressed in Doris Duke's will, experiments that use animals or primary tissues derived from animals will not be supported by this program.
This award will provide $150,000 per year for three years to support direct research expenses including salary support, plus $12,000 (8%) for indirect costs. It is anticipated that up to ten awards will be made in 2013.
This competition will employ a two-stage process. A letter of intent (LOI) must be submitted electronically through the foundation’s application website. Submitting an LOI does not obligate you to submit a proposal. Nonetheless, proposals will not be accepted unless an LOI has been submitted. For applicants wishing to get a head start on their proposal, you may access the full proposal instructions here.
Please note that we are providing the full proposal instructions for reference only. The website to submit your full proposal will not be available until March 20, 2013, and will only be available to individuals who have submitted a Letter of Intent by the deadline of 3 p.m. EDT on March 14, 2013.
A full explanation of the eligibility requirements is available in the Request for Letters of Intent.
- Hold an advanced doctoral degree (M.D., Ph.D., M.D./Ph.D., or the equivalent) and a full-time faculty level appointment (Instructor, Assistant Professor, Associate Professor, or Professor).
- Be affiliated with a U.S.-based institution that is exempt from federal income taxation as an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the "Code") and must not be a private foundation or a Type III supporting organization as defined in Section 509(a) of the Code.
- Propose a research project that meets DDCF’s definition of clinical research as stated in the Request for Letters of Intent.
- Propose a research project that does not utilize animals or primary tissues derived from animals.
- Submit only one application as principal investigator.
Due to the large volume of inquiries about this program, please do not call.
Inquiries will be answered within two business days.
Rationale & Program History
The Medical Research Program created the Innovations in Clinical Research Award to promote collaborations and catalyze breakthroughs in targeted disease areas. We believe that the potential of scientific discoveries to spur field-changing advances increases when new multidisciplinary perspectives are brought into the problem-solving process.
Since 2000, 56 awards totaling approximately $16 million have supported innovative clinical research in cardiovascular disease, stroke, blood disorders, sickle cell disease, and the development of diagnostics and therapeutic monitoring of AIDS in resource-poor countries.
Inquiries and Contact Information
Investigators who identify a grant, award or fellowship program that restricts the number of applications that can be submitted from an Institution should immediately contact their Chairperson, Associate Dean for Research (or Dean, if no ADR) and the Office of Research (see below) if they intend to prepare a response. Failure to do so, or to meet the deadlines for submission of pre-proposal, will preclude submission of the application through the Office of Sponsored Programs.
For general inquiries, or to request a listing of a limited submission opportunity that should be but is not already listed, please email us at firstname.lastname@example.org.